Actively Recruiting
Effects of Diazoxide on Liver Fat Production and Insulin Resistance in Adults with Obesity and MASLD
Led by Columbia University · Updated on 2026-07-06
25
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating how lowering insulin levels with diazoxide affects liver fat production in people with obesity, insulin resistance, and metabolic dysfunction-associated steatotic liver disease MASLD. This single-center, randomized, double-blind, placebo-controlled crossover study explores the role of high insulin in driving excess liver fat creation, aiming to better understand the connection between insulin resistance and MASLD. Participants will undergo two 1-week treatment periods separated by 4 to 12 weeks. In the first period, all will receive placebo doses twice daily. In the second, 80% will receive diazoxide oral suspension at 2 mg per kg body weight twice daily, while 20% will receive placebo again. During both periods, participants will consume 18 doses of heavy deuterated water to measure liver fat production. Blinding is maintained by covering syringes with labels. Throughout the study, participants will provide fasting blood and saliva samples on four mornings and undergo insulin suppression tests to assess insulin resistance at the end of each period. Researchers will compare blood tests before and after treatments to evaluate liver fat production, insulin levels, glucose, and lipid parameters. The study helps clarify how reducing insulin secretion influences metabolic processes related to MASLD and insulin resistance.
CONDITIONS
Brief Title
Effect of Insulin Lowering on Lipogenesis
Research Team
I
Ishwari Nagnur, BA
J
Joshua Cook
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here